1)The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995
2)峰松一夫,他:発症3時間以内の虚血性脳血管障害に対するCMK-527(アルテプラーゼ)静注療法臨床試験の結果.脳卒中26:603-606, 2004
3)日本脳卒中学会医療向上・社会保険委員会 rt-PA(アルテプラーゼ)静注療法指針部会:rt-PA(アルテプラーゼ)静注療法適正治療指針.2005年10月
4)Kleindorfer D, et al:Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke;A population-based study. Stroke 35:e27-29, 2004〔Epub 2004 Jan 22〕
5)Hacke W, et al:Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 359:1317-1329, 2008
6)篠原幸人,他:脳卒中治療ガイドライン2009,協和企画,2009
7) Hacke W, et al:Association of outcome with early stroke treatment;Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-774, 2004
8)Sato S, et al:Impact of the approval of intravenous recombinart tissue plasminogen activator therapy on the processes of acute stroke management in Japan;the SUMO study. Stroke 40:30-34, 2009
9)Lopez-Yunez AM, et al:Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 32:12-16, 2001
10)Ikeda M, et al:Using vital signs to diagnose impaired consciousness;Cross sectional observational study. BMJ 325:800, 2002
11)Goldstein LB, Simel DL:Is this patient having a stroke? JAMA 293:2391, 2005